Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07291102 · ClinicalTrials.gov registry record · Phase 3
Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma
A Phase 3 study, sponsored by Nationwide Children's Hospital.
- Not yet
- Registry status
- Phase 3
- Development phase
- 96
- Enrollment target
NCT07291102 is a Phase 3 study that has not yet begun recruiting, run by Nationwide Children's Hospital. The registered enrollment target is 96 participants.
The verdict
NCT07291102, a Phase 3 study, has not yet begun recruiting, sponsored by Nationwide Children's Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 96 participants
- Enrollment target
Study Summary
This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
Interventions
- DRUG Bridging Chemotherapy
- DRUG Induction Cycles A1-A3
- DRUG Induction Cycles A4-5
- DRUG Consolidation Cycle A6
- DRUG HIT-SKK Chemotherapy Cycles B1-3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2038-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07291102
The ClinicalTrials.gov registry entry for NCT07291102 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bridging Chemotherapy is the first listed.
NCT07291102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07291102 about?
NCT07291102 is a clinical study titled "Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma". This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).
What is the current status of trial NCT07291102?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 96 participants. The study started on 2026-07-01. Estimated completion is 2038-10.
What interventions are being tested in trial NCT07291102?
The interventions under investigation include: Bridging Chemotherapy (DRUG), Induction Cycles A1-A3 (DRUG), Induction Cycles A4-5 (DRUG), Consolidation Cycle A6 (DRUG), HIT-SKK Chemotherapy Cycles B1-3 (DRUG).
Who is sponsoring clinical trial NCT07291102?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.